MYOBLOC Patient Assistance Programs

Solstice Neurosciences, LLC is dedicated to offering access to treatment with MYOBLOC to eligible patients* who are subject to financial hardship. Both a Patient Assistance Program (PAP) and a Co-Pay Assistance Program are available.

The PAP program provides financial support to eligible patients* who are uninsured, not covered by alternate funding sources, and meet both clinical treatment criteria and specific Federal Poverty Level (FPL) guidelines.

The Co-Pay Assistance Program assists eligible patients* with actual out-of-pocket treatment costs (i.e., drug co-pay cost) for MYOBLOC excluding Medicare, Medicaid, TRICARE^®, FEP and Massachusetts’ residents.

You can complete a PAP enrollment form or a Co-Pay Assistance enrollment form to determine if your patient meets our eligibility requirements for either program. You can also enroll online for these programs, or fax enrollment forms toll-free to 888-343-3275.

*Available if patient meets program eligibility criteria.

NOTE: Reimbursement services are available only for those patients being treated with MYOBLOC for a therapeutic condition for which there is a reasonable expectation of reimbursement from a third-party payer. Physicians are responsible for identifying the clinical indication(s) and documenting medical necessity for any use of MYOBLOC. Questions regarding the clinical use of MYOBLOC should be directed to 1-888-461-2255.

See Important Safety Information below.

Important Safety Information

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses. (See WARNINGS, PRECAUTIONS, and OVERDOSE sections of full Prescribing Information).

MYOBLOC^® (rimabotulinumtoxinB) Injection is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.

Before administering MYOBLOC, physicians should consult the full Prescribing Information and Medication Guide.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. The vast majority of these adverse events were mild to moderate, temporary, self-resolving, and more common with higher doses. These adverse events may occur within the first week following treatment and may have a duration of several months. In controlled clinical trials, few patients (<1%) stopped treatment due to dry mouth or dysphagia. There is a reduced frequency of dry mouth and dysphagia reported with continued treatment. Dysphagia has commonly been reported by patients treated with all botulinum toxins for cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (e.g., amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (e.g., motor neuropathy) or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

Click here for Important Safety Information, full Prescribing Information and Medication Guide.

MYOBLOC is a registered trademark of Solstice Neurosciences, LLC,
a wholly-owned subsidiary of US WorldMeds, LLC.
© 2012 US WorldMeds, LLC USWM-MYO494-0911

Important Safety Information | Prescribing Information Terms of Use | Privacy Policy